Your browser doesn't support javascript.
loading
Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands.
Ector, Geneviève I C G; Geelen, Inge G P; Dinmohamed, Avinash G; Hoogendoorn, Mels; Westerweel, Peter E; Hermens, Rosella P M G; Blijlevens, Nicole M A.
Afiliação
  • Ector GICG; Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands.
  • Geelen IGP; Department of Hematology, Albert Schweitzer Hospital, Dordrecht, Netherlands.
  • Dinmohamed AG; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
  • Hoogendoorn M; Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Westerweel PE; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Hermens RPMG; Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Blijlevens NMA; Department of Hematology, Medical Center Leeuwarden, on behalf of the HemoBase Population Registry Consortium, Leeuwarden, Netherlands.
Leuk Lymphoma ; 64(2): 424-432, 2023 02.
Article em En | MEDLINE | ID: mdl-36369821
ABSTRACT
Suboptimal guideline adherence in chronic myeloid leukemia (CML) care is associated with worse treatment outcomes. Current study focused on adherence to seven quality indicators (QIs) based on the European Leukemia Network guideline (one diagnostic, one therapeutic, and five monitoring indicators). Data were obtained from population-based registries in the Netherlands of 405 newly diagnosed chronic phase CML patients between January 2008 and April 2013. Compliance rates regarding diagnostic and therapeutic indicator were 83% and 78%, respectively. Monitoring indicators rates were lower 21-27% for indicators concerning the first year and 58% and 62% for the second and third year, respectively. Noncompliance occurred mostly due to non-timely monitoring. Twenty cases did not comply with any indicator, 6% complied with all indicators. After adjustment for age, overall survival rates did not differ significantly between the groups. Adherence to guideline-based QIs was suboptimal. This demonstrates the evidence-practice gap, shows room for improvement and underscores the need for real-world data.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Leucemia Mieloide de Fase Crônica Tipo de estudo: Guideline Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Leucemia Mieloide de Fase Crônica Tipo de estudo: Guideline Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article